Sohaib Aftab Ahmad Chaudhry
Sohaib Aftab Ahmad Chaudhry has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Rida Shakeel
Department of Surgery, Dow Medical College, Karachi, Pakistan
5 shared publications - Aafeen Mujeeb
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publication - Alishba Fatima
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Amal Tahir
Department of Surgery, Dow Medical College, Karachi, Pakistan
1 shared publication - Ammad Uddin
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Anas Mansour
Faculty of Medicine Al‐Azhar University Cairo Egypt
1 shared publication
Latest Publications
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- Open Access
- 7 May 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Transcatheter edge-to-edge repair and left ventricular assist devices for secondary mitral regurgitation in advanced heart failure: a scoping review
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.
- 7 May 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Open AccessTranscatheter edge-to-edge repair and left ventricular assist devices for secondary mitral regurgitation in advanced heart failure: a scoping review
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.
- Open Access
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e47132
Trends and mortality due to acute respiratory distress syndrome in the United States (1999–2023): A 25-year nationwide study
Acute respiratory distress syndrome (ARDS) remains a significant cause of morbidity and mortality in the United States. Although advances in critical care have improved outcomes, the Coronavirus Disease of 2019 (COVID-19) pandemic substantially altered ARDS epidemiology, necessitating updated analyses of national mortality trends. To examine 25-year trends (1999–2023) in ARDS-related mortality across demographic, geographic, and urbanization categories, and to evaluate the impact of the COVID-19 pandemic on these patterns. We conducted a population-based descriptive study using CDC WONDER multiple cause-of-death data. ARDS-related deaths were identified by ICD-10 code J80. Crude and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal changes were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals. Mortality rates were stratified by sex, age, race/ethnicity, census region, state, and urban–rural classification. Between 1999 and 2023, 364,924 ARDS-related deaths were recorded. National AAMRs declined steadily from 1999 to 2018 (APC −2.63; 95% confidence interval (CI): −4.74–−1.04), surged sharply during 2018 to 2021 (APC 85.78; 95% CI: 53.65–109.16), and decreased between 2021 and 2023 (APC −59.59; 95% CI: −68.58–−47.89), resulting in an overall AAPC of −1.90 (95% CI: −3.80–0.19). Males consistently exhibited higher mortality rates than females. Individuals aged ≥ 75 years had the highest AAMRs. Non-Hispanic Black, Hispanic/Latino, and American Indian/Alaska Native populations experienced disproportionately elevated mortality. Rural areas and the South and Midwest regions showed greater increases during the pandemic. California, Texas, Florida, and New York reported the highest cumulative death counts. ARDS mortality in the United States declined for nearly 2 decades but rose sharply during the COVID-19 pandemic, highlighting persistent disparities by age, sex, race, geography, and urbanization. Targeted interventions and equitable critical care access are essential to reduce future ARDS-related deaths. Detailed Visual Abstract is illustrated in the Central Illustration.
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e47132
Open AccessTrends and mortality due to acute respiratory distress syndrome in the United States (1999–2023): A 25-year nationwide study
Acute respiratory distress syndrome (ARDS) remains a significant cause of morbidity and mortality in the United States. Although advances in critical care have improved outcomes, the Coronavirus Disease of 2019 (COVID-19) pandemic substantially altered ARDS epidemiology, necessitating updated analyses of national mortality trends. To examine 25-year trends (1999–2023) in ARDS-related mortality across demographic, geographic, and urbanization categories, and to evaluate the impact of the COVID-19 pandemic on these patterns. We conducted a population-based descriptive study using CDC WONDER multiple cause-of-death data. ARDS-related deaths were identified by ICD-10 code J80. Crude and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal changes were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals. Mortality rates were stratified by sex, age, race/ethnicity, census region, state, and urban–rural classification. Between 1999 and 2023, 364,924 ARDS-related deaths were recorded. National AAMRs declined steadily from 1999 to 2018 (APC −2.63; 95% confidence interval (CI): −4.74–−1.04), surged sharply during 2018 to 2021 (APC 85.78; 95% CI: 53.65–109.16), and decreased between 2021 and 2023 (APC −59.59; 95% CI: −68.58–−47.89), resulting in an overall AAPC of −1.90 (95% CI: −3.80–0.19). Males consistently exhibited higher mortality rates than females. Individuals aged ≥ 75 years had the highest AAMRs. Non-Hispanic Black, Hispanic/Latino, and American Indian/Alaska Native populations experienced disproportionately elevated mortality. Rural areas and the South and Midwest regions showed greater increases during the pandemic. California, Texas, Florida, and New York reported the highest cumulative death counts. ARDS mortality in the United States declined for nearly 2 decades but rose sharply during the COVID-19 pandemic, highlighting persistent disparities by age, sex, race, geography, and urbanization. Targeted interventions and equitable critical care access are essential to reduce future ARDS-related deaths. Detailed Visual Abstract is illustrated in the Central Illustration.
- Open Access
- 15 July 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (7) , e70180
Trends in Sudden Cardiac Death Related Mortality in Adults in the United States: A CDC WONDER Database Analysis, 1999–2020
Background: Sudden cardiac death (SCD) is a leading cause of mortality in the United States, with significant variations across demographic and geographic factors. This study analyzes trends in SCD‐related mortality among adults (> 25 years) from 1999 to 2020 using the CDC WONDER database.Methods: We extracted data on SCD‐related deaths (ICD‐10 code I46.1) and calculated age‐adjusted mortality rates (AAMR) per 100 000 population, stratified by sex, race/ethnicity, urbanization, and census region. Joinpoint regression was performed to estimate the annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals (CI).Results: A total of 279 599 SCD‐related deaths were recorded from 1999 to 2020. Overall AAMR declined significantly (AAPC: −1.20%; 95% CI: −1.58% to −0.82%) until 2018, followed by a sharp increase from 2018 to 2020 (APC: +6.93%; 95% CI: +3.04% to +10.96%). Declines were most pronounced in American Indian/Alaska Native populations (−3.67%), while the highest increases post‐2018 were observed in Hispanic (+13.1%) and Asian/Pacific Islander groups (+12.3%). Urban areas experienced greater post‐2018 increases compared to rural areas. Regional disparities were evident, with the West showing the steepest rise in mortality.Conclusion: While SCD mortality declined from 1999 to 2018, a concerning reversal has emerged since 2018, particularly in specific racial/ethnic groups and urban areas. Further research is needed to investigate underlying causes, including the potential impact of COVID‐19, healthcare disparities, and lifestyle factors.
- 15 July 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (7) , e70180
Open AccessTrends in Sudden Cardiac Death Related Mortality in Adults in the United States: A CDC WONDER Database Analysis, 1999–2020
Background: Sudden cardiac death (SCD) is a leading cause of mortality in the United States, with significant variations across demographic and geographic factors. This study analyzes trends in SCD‐related mortality among adults (> 25 years) from 1999 to 2020 using the CDC WONDER database.Methods: We extracted data on SCD‐related deaths (ICD‐10 code I46.1) and calculated age‐adjusted mortality rates (AAMR) per 100 000 population, stratified by sex, race/ethnicity, urbanization, and census region. Joinpoint regression was performed to estimate the annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals (CI).Results: A total of 279 599 SCD‐related deaths were recorded from 1999 to 2020. Overall AAMR declined significantly (AAPC: −1.20%; 95% CI: −1.58% to −0.82%) until 2018, followed by a sharp increase from 2018 to 2020 (APC: +6.93%; 95% CI: +3.04% to +10.96%). Declines were most pronounced in American Indian/Alaska Native populations (−3.67%), while the highest increases post‐2018 were observed in Hispanic (+13.1%) and Asian/Pacific Islander groups (+12.3%). Urban areas experienced greater post‐2018 increases compared to rural areas. Regional disparities were evident, with the West showing the steepest rise in mortality.Conclusion: While SCD mortality declined from 1999 to 2018, a concerning reversal has emerged since 2018, particularly in specific racial/ethnic groups and urban areas. Further research is needed to investigate underlying causes, including the potential impact of COVID‐19, healthcare disparities, and lifestyle factors.
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4356-4361
The relation between C-reactive protein (CRP) and risk of incident heart failure in patients with cardiovascular disease: a narrative review
Cardiovascular disease (CVD) remains a leading global cause of morbidity and mortality, with heart failure (HF) significantly contributing to this burden. Elevated C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in the pathogenesis of various cardiovascular conditions, including HF. This narrative review examines the relationship between CRP levels and the risk of incident HF in patients with pre-existing CVD. By synthesizing findings from prospective cohort studies, clinical trials, and meta-analyses, we aim to assess the potential role of CRP as a predictive biomarker for HF onset. Inflammation is a critical component in HF pathophysiology, contributing to myocardial remodeling, fibrosis, and endothelial dysfunction. High-sensitivity CRP (hs-CRP) assays allow for the detection of low-grade inflammation, offering improved risk stratification for cardiovascular events. Studies indicate that elevated hs-CRP levels correlate with an increased risk of myocardial infarction, stroke, and HF development. However, CRP’s specificity as a marker remains a challenge due to its association with various systemic inflammatory conditions. Recent research has explored CRP’s role in HF subtypes, particularly HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Despite growing evidence linking CRP to HF, gaps remain in understanding its mechanistic role, optimal clinical thresholds, and therapeutic implications. Future research should focus on mechanistic studies elucidating CRP’s direct impact on myocardial dysfunction, subgroup-specific analyses, and interventional trials targeting CRP-driven inflammation. Addressing these gaps could significantly improve HF prevention and management by leveraging CRP as a viable prognostic and therapeutic target.
- 13 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4356-4361
Open AccessThe relation between C-reactive protein (CRP) and risk of incident heart failure in patients with cardiovascular disease: a narrative review
Cardiovascular disease (CVD) remains a leading global cause of morbidity and mortality, with heart failure (HF) significantly contributing to this burden. Elevated C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in the pathogenesis of various cardiovascular conditions, including HF. This narrative review examines the relationship between CRP levels and the risk of incident HF in patients with pre-existing CVD. By synthesizing findings from prospective cohort studies, clinical trials, and meta-analyses, we aim to assess the potential role of CRP as a predictive biomarker for HF onset. Inflammation is a critical component in HF pathophysiology, contributing to myocardial remodeling, fibrosis, and endothelial dysfunction. High-sensitivity CRP (hs-CRP) assays allow for the detection of low-grade inflammation, offering improved risk stratification for cardiovascular events. Studies indicate that elevated hs-CRP levels correlate with an increased risk of myocardial infarction, stroke, and HF development. However, CRP’s specificity as a marker remains a challenge due to its association with various systemic inflammatory conditions. Recent research has explored CRP’s role in HF subtypes, particularly HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Despite growing evidence linking CRP to HF, gaps remain in understanding its mechanistic role, optimal clinical thresholds, and therapeutic implications. Future research should focus on mechanistic studies elucidating CRP’s direct impact on myocardial dysfunction, subgroup-specific analyses, and interventional trials targeting CRP-driven inflammation. Addressing these gaps could significantly improve HF prevention and management by leveraging CRP as a viable prognostic and therapeutic target.
- Open Access
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 7
Addressing Rural-Urban Disparities in Access to Renal Transplantation in Pakistan: A Narrative Review
Background: Pakistan’s healthcare system is marked by stark rural-urban disparities, with 62% of the population residing in rural areas but only 20% of transplant facilities located outside major cities like Karachi and Lahore. This inequity exacerbates the burden of end-stage renal disease (ESRD) for rural patients, who often cannot afford travel or treatment costs. Objective: This narrative review assesses rural-urban disparities in access to renal transplantation in Pakistan and explores strategies to improve equity in transplant care. Methods: We analyzed hospital data, patient registries, and policy reports from 2015 to 2024, focusing on transplant outcomes and access challenges in rural Punjab, Sindh, and Khyber Pakhtunkhwa. We also reviewed mobile health initiatives and public-private partnership models. Results: Rural patients face a 40% lower likelihood of receiving a transplant compared to urban patients, primarily due to transportation barriers and lack of local dialysis centers. Only 5% of rural ESRD patients are referred to transplant centers annually. Initiatives like SIUT’s mobile dialysis units have reached 10,000 rural patients since 2018, but transplant follow-up remains challenging due to limited local expertise. Conclusion: Bridging rural-urban disparities requires decentralized transplant care, mobile health units, and training for rural healthcare providers. Future research should focus on cost-effective models to expand transplant services to underserved regions.
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 7
Open AccessAddressing Rural-Urban Disparities in Access to Renal Transplantation in Pakistan: A Narrative Review
Background: Pakistan’s healthcare system is marked by stark rural-urban disparities, with 62% of the population residing in rural areas but only 20% of transplant facilities located outside major cities like Karachi and Lahore. This inequity exacerbates the burden of end-stage renal disease (ESRD) for rural patients, who often cannot afford travel or treatment costs. Objective: This narrative review assesses rural-urban disparities in access to renal transplantation in Pakistan and explores strategies to improve equity in transplant care. Methods: We analyzed hospital data, patient registries, and policy reports from 2015 to 2024, focusing on transplant outcomes and access challenges in rural Punjab, Sindh, and Khyber Pakhtunkhwa. We also reviewed mobile health initiatives and public-private partnership models. Results: Rural patients face a 40% lower likelihood of receiving a transplant compared to urban patients, primarily due to transportation barriers and lack of local dialysis centers. Only 5% of rural ESRD patients are referred to transplant centers annually. Initiatives like SIUT’s mobile dialysis units have reached 10,000 rural patients since 2018, but transplant follow-up remains challenging due to limited local expertise. Conclusion: Bridging rural-urban disparities requires decentralized transplant care, mobile health units, and training for rural healthcare providers. Future research should focus on cost-effective models to expand transplant services to underserved regions.